GRIT and Quangang Partner to Boost Interleukin-2 Localization

Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) have announced a new strategic partnership to enhance their R&D capabilities in innovative T-cell therapies. The collaboration aims to develop a standardized Interleukin-2 (IL-2) treatment for solid tumor patients, making it affordable and accessible for Chinese patients.

The primary goal of this partnership is to expand the use of Quanqi (125SER) Interleukin-2 (I) products for treating solid tumors. Quanqi (125SER) is already approved in China for the treatment of various solid tumors, including renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, and lung cancer. The focus will be on creating a domestically produced alternative to the globally recognized IL-2 cytokine used in T-cell therapy, addressing critical medical needs for cancer patients in China.

Grit Biotechnology specializes in cell therapy and leads the development of tumor infiltrating lymphocytes (TILs) therapy in China. Their non-gene-engineered TIL program, GT101, is currently in Phase 2 pivotal trials. This program is the fastest pipeline for TIL therapy in China, with plans to file for Biologics License Application (BLA) in 2025. Quangang Pharmaceutical is a prominent biopharmaceutical company focused on genetic medicines. It has GMP facilities and a dedicated biotechnology research institute. Both companies bring extensive technical expertise and product development experience, along with significant influence in China's biopharmaceutical industry.

Through this alliance, GRIT aims to leverage its expertise in T-cell therapy to accelerate the development and commercialization of cell therapy products. This partnership is expected to provide a wider range of treatment options and instill hope for more solid tumor patients in China. Both companies believe that their combined efforts will enable more Chinese patients to access advanced and effective T-cell treatments with an affordable IL-2 product.

In conclusion, this strategic partnership between GRIT and Quangang is set to revolutionize cancer treatment in China by developing accessible and affordable IL-2 therapy for solid tumor patients. The collaboration combines the strengths of both companies to address unmet medical needs and improve the lives of Chinese cancer patients.